Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Mengyao Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8951-5075; OpenAlex author ID A5039253823. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

  1. Nano-enabled repurposing of Benproperine phosphate enhances pancreatic Cancer chemotherapy through lethal autophagy arrest and immune activation. Co-author DOI 10.1016/j.jconrel.2025.114187↗
  2. Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Co-author DOI 10.3389/fonc.2023.1118633↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 2 shared papers, 2023–2025 · strength 0.42
  2. Jianxin Wang · 1 shared paper, 2023 · strength 0.22
  3. Qi Zhang · 1 shared paper, 2023 · strength 0.22
  4. Qihan Fu · 1 shared paper, 2023 · strength 0.22
  5. Xiaobao Wei · 1 shared paper, 2025 · strength 0.20
  6. Jiangchao Wu · 1 shared paper, 2025 · strength 0.20
  7. Zhe Zhang · 1 shared paper, 2025 · strength 0.20
  8. Yi Zang · 1 shared paper, 2025 · strength 0.20
  9. Qi Zhang · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.